Results 141 to 150 of about 38,272 (314)

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen   +7 more
wiley   +1 more source

Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial) [PDF]

open access: yes, 2017
Introduction: The primary aim of this study is to compare the efficacy of three short-term glucose-lowering interventions (exercise, metformin and dapagliflozin) on glycaemic variability in overweight or obese men and women with elevated diabetes risk ...
Amadid, Hanan   +6 more
core   +1 more source

Unlocking Synergistic Hepatoprotection: Dapagliflozin and Silymarin Combination Therapy Modulates Nuclear Erythroid 2-Related Factor 2/Heme Oxygenase-1 Pathway in Carbon Tetrachloride-Induced Hepatotoxicity in Wistar Rats

open access: yesBiology
Simple Summary This study explored the liver-protective effects of dapagliflozin and silymarin, alone and combined, against liver damage caused by carbon tetrachloride (CCl4) in rats. Thirty rats were divided into five groups.
S. Satyam   +7 more
semanticscholar   +1 more source

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı   +4 more
wiley   +1 more source

Effect of preoperative SGLT2 inhibitor use on postoperative acute kidney injury in patients with type 2 diabetes undergoing surgery: A causal inference study using routinely collected data

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess whether preoperative sodium‐glucose co‐transporter 2 inhibitor (SGLT2i) use reduces the odds of postoperative acute kidney injury (AKI) in patients with type 2 diabetes undergoing surgery. Methods We conducted a target trial emulation using inverse probability of treatment weighting, utilising routinely collected data from a ...
Frank M. Gao   +7 more
wiley   +1 more source

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Sotagliflozin, an inhibitor of sodium‐glucose co‐transporter (SGLT)‐1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects. The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D).
Massimo Nardone   +6 more
wiley   +1 more source

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

open access: yesJournal of Internal Medicine, EarlyView.
Abstract Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients.
Holly J. Kramer, George L. Bakris
wiley   +1 more source

The Beneficial Effect of the SGLT2 Inhibitor Dapagliflozin in Alleviating Acute Myocardial Infarction-Induced Cardiomyocyte Injury by Increasing the Sirtuin Family SIRT1/SIRT3 and Cascade Signaling

open access: yesInternational Journal of Molecular Sciences
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have a variety of cardiovascular and renoprotective effects and have been developed as novel agents for the treatment of heart failure. However, the beneficial mechanisms of SGLT2i on cardiac tissue need
Yi-Hsiung Lin   +10 more
semanticscholar   +1 more source

Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome

open access: yesExperimental Physiology, EarlyView.
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy